Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“Do” a phase 3 trial implies that they actually did one. They did not finish therefore they did jack all. Would you say they did a phase 3 if they enrolled 1 patient?
Steaming Bullshite
a little update from an analyst... I don't think they is anything too new her, but ... "develop a defined recruitment plan" - implies that they are back to Base one IMO.
https://www.proactiveinvestors.com/companies/news/1016408/revive-therapeutics-staying-the-course-on-phase-3-trial-of-bucillamine-in-covid-19-patients-after-meeting-with-fda-1016408.html
That's a great accomplishment bro, where's the money?
Dude...when MF was funding that last round I just shook my head. Unbelievable.
Do not confuse "borderline useless" foul noise making non shareholders with a real Public CEO, running one of the few, possibly the only OTC stock, $RVVTF , to ever fund and do a phase III drug trial in US History, as an OTC stock
Do not confuse the routine use of SEC/FDA/Legal mandated legalize language with a sell signal. That is an amateur mistake. Even stocks like Pfizer, Amazon and Google use the same language.
This is super bullish.
I wonder about those who funded the last dilution round at .15 and never saw green. Lost 2/3rds in a matter of weeks
That’s not deer looking at headlights
That’s road kill bro
You're an idiot! Don't text me again.
So many assumptions made by you idiots!
You are absolutely correct. 100%. Stringing investors along has been the clear and obvious strategy by MF for a very long time and it has made him a very good living. A country club living in fact. The vast majority of this board are deer in the headlights.
Revive's Bucillamine is still by far one the best opportunities across the dire OTCM at present. At this stage of their trials (and related FDA & industry exposure) plus the current low share price, the risk/reward is well worth me continuing taking personally.
I believe in Revive's Bucillamine. Now sell me your cheap shares and good luck!
Dude the ceo is borderline useless at this point. He is going to push this back another month just to get initial results? That is ridiculous. He doesn’t have a clue what he is doing which is why everything takes 3x as long as it should. He should have taken the help that was offered. I hope he gets fined 10x as much as he has made “running” this company for all his lies and stringing shareholders along.
With this news and at the current share price, I will not sell a single share. I know of several penny stocks with so much promise that took years for them to take off. Revive is no different and at least things are happening, What's another couple of years LOL, GLTA!
The Company "believes"
"could" support further discussions
"potential" new clinical studies
He's been doing this to you for 3 years now. What's it going to take?
Cw,
I did like this part,The Company plans to complete its initial evaluation of the Study’s data with an independent biostatistician team by the end of June. The Company believes that once it has completed the evaluation of the Study’s data, it could support further discussions with the FDA on potential new clinical studies and allow the opportunity to work with potential domestic and international pharmaceutical partners to determine a suitable regulatory pathway for approval of Bucillamine based on the evaluated Study’s data.
Ps.. expect the data by the end of June . Hopefully..
Pps. We wait some more and more lol :) holding not selling any this low unless I have to....
The wheels are still in motion, albeit slow motion.
https://revivethera.com/2023/05/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-bucillamine-in-the-treatment-of-covid-19-4/
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
https://www.stocktitan.net/news/RVVTF/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-cftqzipsz44v.html
Rubberneck doing dd :)
Ps. I buy cnna if we are down with outcome there are connections to make money back:)
But holding my Balls to;)
Ps. I think I need more edibles for the wait lol
Some interesting listening.....
This is the most important video you will watch this year. Millions were killed with Covid-19 for profit.
— Kim Dotcom (@KimDotcom) May 25, 2023
“Covid-19 was an act of biological warfare perpetrated on the human race. It was a financial heist. Nature was hijacked. Science was hijacked.” pic.twitter.com/1sYnVMaIRN
Yeah like lemmings over the cliff. A rabbit hole cult that has nothing left except shooting the messengers.
No cliff here yet. Just in your own head.
Sheep here Joe. They followed a pumper over a cliff
Let me spell it out for you pal. You...are...not...getting...your...money...back.
"What is toxic positivity? Toxic positivity is the pressure to only display positive emotions, suppressing any negative emotions, feelings, reactions, or experiences. It invalidates human experience and can lead to trauma, isolation, and unhealthy coping mechanisms."
-Betterup.com
China is bracing for a massive new wave of COVID cases. What it means for the rest of the world
BYERIN PRATER
May 24, 2023 at 4:00 AM EDT
People visit a traditional spring festival flower market, which reopened after closure due to the spread of COVID, in Guangzhou, China, on Jan. 20. Cases of Omicron variant XBB are mounting in China, forming a new wave expected to crest around 65 million cases a week by the end of June.
PHOTO BY STR/AFP VIA GETTY IMAGES
Cases of Omicron variant XBB are mounting in China, forming a new wave expected to crest around 65 million cases a week by the end of June.
Infections will likely reach 40 million per week by the end of the month, senior health adviser Zhong Nashan told attendees at a biotech conference in Guangzhou, according to Bloomberg.
The wave could swell to become the country’s second largest, experts tell Fortune. It will undoubtedly pale in comparison to the country’s first major wave late last year, during which an estimated 37 million people were infected on one day—Dec. 20—alone.
That wave—equivalent to the early days of the pandemic for the rest of the world—occurred after the country abruptly abandoned its yearslong “zero COVID” policy, effectively letting the virus “rip” through a population that had been largely sheltered from the it—and that was vastly undervaccinated.
A ‘largely invisible’ wave
XBB, the “first major highly immune-evasive” group of COVID variants, “will sweep through China,” but the wave will be “largely invisible” due to low rates of testing and reporting, Raj Rajnarayanan, assistant dean of research and associate professor at the New York Institute of Technology campus in Jonesboro, Ark., and a top COVID-variant tracker, tells Fortune.
When it comes to XBB variants, “the rest of the world has seen them all.” But up until recently, “China hasn’t,” he says, adding that the country has a substantial population at high risk of severe outcomes from COVID due to age, immune status, and co-morbid conditions.
Increased circulation of XBB variants in China—and elsewhere—is likely to result in the evolution of new XBB variants, Rajnarayanan said. So far, XBB spawn have remained relatively innocuous for those not at increased risk of severe disease, according to the World Health Organization’s latest situation report, released Thursday.
‘Go back for regular check-ups’
It remains to be seen whether hospitalizations will rise in China, Rajnarayanan and fellow variant tracker Ryan Gregory—a Canadian biologist who has assigned “street names” to so-called “high flying” variants like XBB.1.5, dubbed “Kraken”—tell Fortune.
Hospitalizations can, however, be expected to rise if variants that combine the transmissibility of XBB with the lung involvement of Delta catch on, in China or elsewhere. Trackers are eyeing variants that have a mutation in the spike protein that could cause such a phenomenon. So far, such variants are only prevalent in New Zealand and the European Union, Rajnarayanan says.
The evolution of a veritable XBB-Delta combo isn’t an inevitability, though, Rajnarayanan says.
And while the virus is capable of pivoting at any point, evolving into a more lethal version of itself, it so far hasn’t–—and the chance of it doing so isn’t any greater in China that it is in the rest of the world, where the virus is also spreading unchecked, Dr. Ali Mokdad, a professor at the University of Washington’s Institute for Health Metrics and Evaluation, tells Fortune.
While caution is always warranted when it comes to COVID, people everywhere need to “go back for regular check-ups, and bring their kids in for vaccinations,” Mokdad said.
COVID precautions “saved a lot of lives,” he added. “It’s time for us to go back to normal and make sure it’s not at the expense of other preventative programs.”
Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up today.
Thanks Gator I appreciate the info.
Solid buying for the day…nice.
Ah. That is where the risk factor comes into play. We are hoping that Buccy is the undiscovered wonder drug. If everyone knew about it, and it was used in 50 countries, we could not have the opportunity to make serious money off this stock. If it was so easy, we would have a triple crown winner every year.
ps. I realize we are not making money off this stock at the moment.
pps. Good luck to all even a pissed off and frustrated Snoopy.
ppps. Come on Doug Flutie. We need that Hail Mary more than ever.
There is also a somewhat new face book chat in the F-book group many are positive there, a few good people there also : ) lately not much talk in any of the groups lol because of course just waiting on the data as u know.
ps. holding of course but ignoring the Negative u know whats lol.....
I think Bucillamine could help with something like but we will see.
📌Post-COVID-19 symptoms can linger for 2 years and are associated with prolonged inflammation.
— Outbreak Updates (@outbreakupdates) May 23, 2023
Patients with prolonged inflammation showed elevated terminally differentiated memory T cells in their blood; 54% had symptoms at 12 months. https://t.co/v02bnYT5xf
China’s New Covid Wave Set to See 65 Million Cases a Week ⚠️ https://t.co/4PVEi0SPI1
— Jess (@MeetJess) May 22, 2023
Gaps always fill…..I’m hoping however that we continue upward. May 12 we had a gap down…it’s filling in.
I am not a scientist and neither is Rubber. We believe in the science behind Bucillamine and that it can be used as an antiinflammatory to combat long covid, restore glutathione levels, work 16X as strong as NAC and reduce symptoms such as fever and chills as proven by PCR numbers. I think this will be clear within a few days. It also will be effective in the USA against Rheumatoid Arthritis and several other conditions. Look it up. There are several other conditions that BUCY works for overseas.
ps. Sheesh
pps. Nobody is happy with the PPS, and it's still a longshot, but many of us will hold for a buyout or wait for the mushrooms industry to explode. Several of us averaged down so all we can do is wait and have hope.
Anyone with any sense and a little powder would be taking a step back, calm down, look at that gap and buy while others are bitching like a bunch of woke schoolgirls.
5/12/2023
Must be a leak, news pending, $$$$$$
Because Buc works.
OK, so why is it up over 25% today with heavy volume?
Price
$0.0566
Day's Change
0.0114 (25.22%)
Bid
0.05
Ask
0.0567
B/A Size
610800x10000
Day's High
0.0566
Day's Low
0.0409
Volume(Heavy Day)
422,541
May 22, 2023 2:55pm ET
What are you waiting for? It's over. Stick a fork in it.
Why continue to hope and pray?
The only people waiting are a few pumpers and bagholders. I'm not waiting for anything, and by the looks of this and other message boards the vast majority are done waiting too. What criteria do you need to see before you admit defeat? Come on and tell us what would make you admit defeat. Is there anything? Christians have been waiting over 2000 years. Is that you with bucillamine?
Gov
I not angry at anyone. And I have lost nothing. You have no idea what you are talking about. Stop your bs. Just wait like everyone else.
would have been nice to have them meet a year ago - I don't think the data hasn't changed or patients been enrolled over the past year.
Yes it matters and yes Bucillamine should do well in restoring it.
Hey There Medicinecat,
The FDA or any DSMB isn’t in the business of being impressed by anything. Our sample is just too small to reach statistical significance with the original endpoints of hospitalizations and death even if we would have gotten to 1000 the last 290 or so what have been during the Omicron variant which wouldn’t have helped much, if at all. We haven’t seen the data for the first 210 because at that time the trial was still ongoing but their push to add PCR to the end point as a primary speaks volumes. Add all of the data from Buci’s ugly step sister NAC along with the in vitro studies for Buci show that it should work and work very well. Hindsight is always 20/20 but we would have certainly had the chance to change endpoints and go for an EUA if they would have tracked the symptoms data properly. If we have strong PCR data, symptoms reduction and as a secondary kept folks out of the hospital there will be value here, a lot more than our current market cap which I know isn’t saying much but value none the less!! GLTA
This is not true. As Rick, pointed out the recent endpoint that was submitted was with healthy patients, so it was unlikely that there would be statistical significance that was jaw dropping. However, prior endpoint with pcr data was very good from the first 210 that MF used it as an endpoint even though the FDA did not like the endpoint choice. Clearly, MF saw something he liked from the PCR test to try to push it through. Now, when he looks at symptom data,it will show some kind of time reduction to recover and based on other triggers, ie. glutathione recovery and 16 X NAC in strength, this is sure to have something big.
ps. I hope.
Good afternoon Hattrick. Good to hear from you again. This is all great but your thesis is based on one big "if". IF there is positive data. So far the FDA and the DSMB are not impressed so what makes you believe the 500 is going to reflect something a potential partner would see as valuable enough to get anybody's money back? I agree with what you're saying but so far we have nothing to indicate this trial has produced anything positive. In fact what we have at this point is the opposite.
The new COVID variant has symptoms that are similar to allergies. Here’s how to tell the difference
Is it pink eye, allergies… or COVID?
By TROY FARAH
Staff Writer
PUBLISHED MAY 16, 2023 12:00PM (EDT)
Red eyed man holding tissue to his nose (Getty Images/heidijpix)
Nothing in life is certain except death, taxes and that the SARS-CoV-2 virus will keep mutating. Despite both the White House and the World Health Organization recently declaring an end to the public health emergencies characterizing the last three years of the pandemic, the pathogen responsible for COVID continues to circulate, still daily infecting large numbers of people, sometimes hospitalizing and killing them or giving them long-lasting symptoms.
In the U.S., 1,100 people died from COVID the week ending May 3, so even though recent stats suggest COVID deaths dropped in 2022. Still, the disease ranks fourth among the leading causes of death in the U.S., meaning it is still killing a very high number of Americans.
It's true that infections and death are trending downward and we have better tools than ever to control COVID. But it is also true that viruses naturally mutate, often evolving new strategies to evade our defenses.
Meanwhile, as SARS-CoV-2 mutates, its symptoms often manifest differently. And the latest batch of variants that are spreading in North America appear to have symptoms very similar to allergies, especially conjunctivitis or pink eye. That means many people have COVID, thinking it's just related to the weird, exceptionally bad allergy season. Unfortunately, unlike allergies or the flu, there is nothing "mild" about COVID, not even the most recent variants, whose infections can still cause brain damage and long COVID.
The Centers for Disease Control and Prevention (CDC) keep a weekly tally estimating the total percentage of virus strains currently circulating. All of them right now are the children or grandchildren of the omicron variant that emerged in late 2021. For most of this year, Americans have been battling against Kraken (XBB.1.5), but it is slowly being superseded by its offspring, such as Arcturus (XBB.1.16).
According to CDC data, Kraken made up roughly 67 percent of cases in the week ending May 6, a decline from its peak of 84 percent in April. Meanwhile, Arcturus has jumped to around 12.5 percent of cases, a rise from just 1 percent at the end of March.
While the string of numbers and letters in a variants name may seem confusing — which is why the nicknames exist — they can represent significant differences between virus strains that manifest as entirely different symptoms. They may also allow the virus to better infect different areas of the body. The delta strain, for example, was more likely to infect the lower respiratory tract, while omicron primarily affects the upper respiratory tract, generally causing less damage to the lungs.
It's simple to clear up any confusion about whether it's COVID or allergies: Take a test. Even though the virus is constantly mutating, even the take-home COVID tests will still work typically. That's because they are designed to capture a wide variety of mutations to the N protein, which differs from the spike protein, the part of the virus used to enter our cells.
Arcturus first appeared in India, but as it makes its way through North America, it seems to be presenting feverish symptoms more commonly as well as mimicking allergies, specifically conjunctivitis. Often called pink eye, this is a reddish-pink inflammation or infection of the transparent membrane (conjunctiva) that lines your eyelid and covers the white part of your eyeball. It can be quite itchy and caused by bacteria, allergens or viruses. COVID-related conjunctivitis is seemingly more common in children, but so far, much of this data is anecdotal.
In late April, the American Academy of Ophthalmology issued a report that eye symptoms alone are probably not a sign of COVID infection. But if your kid has been exposed to the virus or have other symptoms, such as a fever, body aches, cough, or the prototypical loss of taste or smell, it's recommended to have them tested.
The vaccines still do a decent job of preventing serious illness and death from these emerging strains of COVID, but their ability to protect against infection is waning. Federal health agencies recently approved a second bivalent booster shot for immunocompromised people or those over age 65.
Does restoration of glutathione matter?
insert-text-here
Does Bucillamine restore glutathione?
Thank you
enjoy the day;0)))
No
Bard is a LLM and doesn't have access to inside information
Followers
|
339
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36630
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |